Evidence map›Paper›PMID 41286064›Full record

ArticleScientific reports2025

M2 macrophages and tumor cells engage in a metabolic feedback loop to drive HCC progression.

Yimin Nong, Xiaolong Chen, Baoxin Zhang, Zhenyin Lin, Wuriniletu, Chengyou Du, Qiang Liu

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. A Darwinian Perspective on Tumor Evolution.International journal of biological sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yimin NongDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xiaolong ChenDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Baoxin ZhangShenzhen Baoan Women's and Children's Hospital, Shenzhen, China.
Zhenyin LinShenzhen Baoan Women's and Children's Hospital, Shenzhen, China.
WuriniletuShenzhen Baoan Women's and Children's Hospital, Shenzhen, China. wrnl@sina.com.
Chengyou DuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. duchengyou@126.com.
Qiang LiuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. doctorliuqiang@126.com.

Funding

Natural Science Foundation of Chongqing cstc2021jcyj-msxmX0292
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) represents a significant global health challenge due to its molecular heterogeneity and the immunosuppressive nature of its tumor microenvironment (TME). Tumor-associated macrophages (TAMs), particularly the M2-polarized subset, are crucial in HCC progression, contributing to immune evasion, angiogenesis, and metastasis. However, the mechanisms driving TAM reprogramming and their metabolic interactions within the TME remain poorly understood. In this study, we applied single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics to identify a novel metabolic-immune axis in HCC. Our findings revealed increased oxidative phosphorylation (OXPHOS) in tumor cells, which correlated with enhanced ribosomal activity in M2 macrophages, suggesting a metabolic coupling between the two. Tumor cells, under elevated OXPHOS, secrete factors that recruit macrophages and promote M2 polarization, thereby reinforcing immune suppression. Further analysis of The Cancer Genome Atlas (TCGA) dataset led to the development of a prognostic model based on OXPHOS-related genes, showing strong predictive power across multiple cohorts. These results suggest a novel OXPHOS-ribosome-M2 polarization axis and offer potential therapeutic targets for immunometabolic therapies in HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMacrophagesTumor-Associated MacrophagesCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticHumansOxidative PhosphorylationPrognosisTumor MicroenvironmentHepatocellular carcinomaMetabolic reprogrammingPrognostic modelSingle-cell RNA sequencingTumor-associated macrophages

Identifiers

PMID41286064
PMCPMC12644919

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.